Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal  by Pérez, M. et al.
Phosphorylated, but not native, tau protein assembles following reaction
with the lipid peroxidation product, 4-hydroxy-2-nonenal
M. Pe¤reza, R. Cuadrosa, M.A. Smithb, G. Perryb, J. Avilaa;*
aCentro de Biolog|¤a Molecular ‘Severo Ochoa’ (CSIC-UAM), Universidad Auto¤noma de Madrid, 28049 Madrid, Spain
bDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA
Received 24 October 2000; revised 21 November 2000; accepted 21 November 2000
First published online 1 December 2000
Edited by Matti Saraste
Abstract A correlation between hyperphosphorylation of tau
protein and its aberrant assembly into paired helical filaments
has lead to suggestions that phosphorylation controls assembly,
but lacked a mechanistic basic. In this work, we have found that
phosphorylated, but not native, tau protein is able to form
polymers after the reaction with 4-hydroxy-2-nonenal, a highly
toxic product of lipid peroxidation. Phosphorylation of tau by
both proline or non-proline directed kinases, was able to assemble
it into polymers. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Alzheimer’s disease (AD) is a neurological disorder charac-
terized, histopathologically, by the presence of two aberrant
structures, senile plaques and neuro¢brillary tangles (NFT).
Since the number of NFT in patients’ brain has been corre-
lated with the level of dementia [1], an extensive analysis of
NFT components has been carried out. NFT are aggregates
of bundles of paired helical ¢laments (PHF), and the major
protein component of PHF is a hyperphosphorylated form of
the microtubule associated protein, tau factor [2,3].
The formation of aberrant tau polymers, like PHF, requires
a conformational change of the protein since there is an in-
creased interaction of PHF^tau, compared to unpolymerized
tau, with conformation-dependent antibodies such as Alz50
[4]. Some conformational changes in tau protein occur as a
consequence of phosphorylation [5], and it is not coincident
that aberrant hyperphosphorylation of tau precedes the for-
mation of NFT in AD [6]. In sum, these ¢ndings suggest that
tau phosphorylation, its conformational change and its poly-
merization could be interrelated aspects. However, in vitro
analysis, to study the assembly of tau into ¢brillar polymers,
has indicated that recombinant, unmodi¢ed or low phosphor-
ylated tau [7^9] is able to polymerize. Also, it has been found
that tau polymerization, in vitro, is favored by the presence of
sulfated glycosaminoglycans (sGAG) [10,11], a component of
NFT that interacts with tau [12], and that in such conditions,
although phosphorylated tau is able to assemble [11] it does
with a lower e⁄ciency than unmodi¢ed tau [13]. These results
could be explained by suggesting the existence of an alterna-
tive mechanism to assemble tau into ¢brillar polymers, one in
which phosphorylated tau could have an increased capacity
for polymerization as compared to unmodi¢ed tau under cer-
tain conditions.
Recently, we found [14] that phosphorylated, but not un-
modi¢ed tau, could change its conformation, becoming reac-
tive with antibody Alz50, when it reacts with 4-hydroxy-2-
nonenal (HNE), a highly reactive product of lipid peroxida-
tion, resulting from oxidative stress [15]. HNE adducts of
protein are increased in vivo in AD patients compared to
controls [16]. These observations suggest that oxidative dam-
age could play a synergistic role with tau phosphorylation to
generate the conformational changes required for PHF for-
mation [14] mediated by the HNE to tau, a binding that was
previously described [17]. In this study we tested if phosphor-
ylated tau, following reaction with HNE, is promoted in as-
sembly.
Our results suggest that, by promoting formation of tau-
¢brillar polymers of phosphorylated tau, HNE may be the
important link between tau phosphorylation and PHF forma-
tion.
2. Materials and methods
2.1. Materials
Okadaic acid was purchased from Sigma. HNE was prepared as
described [18]. Recombinant tau was isolated as indicated [10]. 7.51
Antibody was a kind gift of Dr. C. Wischik (MRC Cambridge, UK).
PHF-1 antibody was a kind gift of Dr. P. Davies (Albert Einstein
College, Bronx, NY, USA); 12E8 antibody was a kind gift of Dr. P.
Seubert (Athena, San Francisco, CA, USA) and Tau-1 antibody was a
kind gift Dr. L. Binder (MGC, IL, USA). H89 was obtained from
Calbiochem. Tau peptide KVTSKCGSLGNIHHKPGGG was syn-
thesized as previously described [10].
2.2. Cell culture
Tau-transfected COS-1 cells were grown in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% heat inactivated fetal calf
serum containing glutamine (2 mM) and antibiotics (penicillin/strep-
tomycin). To these cultures, okadaic acid (1 WM) was added for 0.5^1
h to generate hyperphosphorylated tau.
The action of OA was tested by immuno£uorescence analysis using
tau antibodies (see above) on cultured cells. This was performed as
previously described [19].
2.3. Tau isolation
Hyperphosphorylated tau was obtained from tau-transfected COS-1
cell extracts [20], after incubation with okadaic acid. Soluble protein
was heat treated and the puri¢cation of tau was carried out as pre-
viously described [21]. The protein was characterized by gel electro-
phoresis and immunoblotting.
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To obtain phosphorylated tau lacking the modi¢cation promoted
by GSK3, or PKA, okadaic acid was added to cultures incubated in
the presence of 20 mM LiCl or H89 (10 WM) [22].
2.4. Assembly of tau protein into ¢laments
Filaments were grown by vapor di¡usion on hanging drops con-
taining tau protein (1 mg/ml) in the standard way used for protein
crystallization, as previously indicated [10], but in the absence of
heparin and in the presence of increasing amounts of HNE. The
samples, after incubation for 4 days at 4‡C in a ¢nal volume of 20
Wl, were visualized by electron microscopy as described [23], and the
amount of polymers was quanti¢ed by sedimentation [10].
3. Results
3.1. Isolation and characterization of phosphorylated tau
Since PHF^tau is in a hyperphosphorylated form in vivo
[3], we focused on conditions that promote its polymerization.
To isolate hyperphosphorylated tau, the cDNA, expressing
the protein (the isoform containing four tubulin-binding re-
peats [24]), was transfected in COS-1 cells, and the tau-ex-
pressing cells were incubated with the phosphatase inhibitor
okadaic acid (OA), to increase the level of tau phosphoryla-
tion, an increase that can be followed by its decrease in elec-
trophoretical mobility. Fig. 1A shows that tau isolated from
tau-expressing cells (and OA treated) has a decreased electro-
phoretic mobility compared to that of recombinant tau (con-
taining the same number of tubulin-binding repeats).
To characterize some of the residues that have been modi-
¢ed by phosphorylation in tau protein, three antibodies that
recognize phosphorytable regions, which are modi¢ed in AD,
were tested. These antibodies are: ab Tau-1, reacting with
serines 199 and 202 in unphosphorylated form; ab 12E8, re-
acting with phosphoserine 262; and ab PHF-1 reacting with
serines 396 and 404 in phosphorylated form. The serines re-
acting with ab Tau-1 and ab PHF-1, are modi¢ed by proline
directed protein kinases, like glycogen synthetase kinase 3
(GSK3), whereas that identi¢ed by ab 12E8 is phosphorylated
by a di¡erent type of kinases, like protein kinase A (PKA) or
mitogen associated protein kinase (MAPRK). In order to ob-
tain tau phosphorylated in these and other residues, dephos-
phorylation of tau expressed in cultured cells was prevented
by the addition of the phosphatase inhibitor OA. Fig. 1A
shows the increased phosphorylation state of tau, re£ected
by decreased electrophoretic mobility, under OA treatment.
Fig. 1B, C, D shows the reaction of tau antibodies with phos-
phorylated tau (isolated from transfected cells in the presence
of OA) and with recombinant tau. It indicates that phosphor-
ylated tau is, at least, phosphorylated in the three tau regions
recognized by antibodies Tau-1, 12E8 and PHF-1 (Fig. 1E).
This phosphorylated tau was used for polymerization assays.
As previously indicated, tau protein can be modi¢ed by
proline directed kinases at the region recognized by ab Tau-
1 or ab PHF-1; whereas non-proline directed kinases modify
the site recognized by ab 12E8. In the second case, di¡erent
kinases, like PKA or MAPRK (with di¡erent characteristics
or inhibitors) could be involved in the modi¢cation of tau,
whereas in the ¢rst case it has been indicated that mainly
GSK3 is involved in such tau modi¢cation [22]. In attempt
to inhibit PKA, H89 was used to test if the reaction of ab
12E8 with tau protein was abolished, and it does (Fig. 2). On
the other hand, little is known about inhibitors for MAPRK.
Since LiCl can inhibit GSK3 activity, we isolated tau from
transfected cells incubated with OA and LiCl. In this case, we
found reaction of the modi¢ed tau with ab 12E8 but not with
ab PHF-1 (Fig. 2). This partially modi¢ed tau was also tested
in polymerization assays (see below).
3.2. Assembly in vitro of phosphorylated tau into ¢brillar
polymers
It has been previously indicated that the presence of HNE,
a product resulting from lipid peroxidation, can change the
conformation of phosphorylated, but not unphosphorylated,
tau protein, and that such conformational change could be
identi¢ed by its reaction with the antibody Alz50 [14].
To test if HNE could also promote the assembly of phos-
Fig. 1. Phosphorylation of tau protein. A: Phosphorylated tau protein was puri¢ed from tau cDNA-transfected COS-1 cells, cultured in the
presence of okadaic acid. The modi¢ed protein (right) shows a slower electrophoretic mobility than that of recombinant tau upon reaction with
tau antibody 7.51. B, C and D indicate the reaction of recombinant (left) and phosphorylated (right) tau protein with tau antibodies Tau-1,
12E8 and PHF-1, respectively. The localization of the modi¢ed residues, recognized by ab Tau-1, 12E8 and PHF-1, in tau molecule, is indi-
cated, below in the ¢gure.
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phorylated tau, both compounds were mixed and the poly-
merization of the protein was tested as previously described
[10]. Fig. 2 shows that phosphorylated tau (Fig. 2F), but not
recombinant tau (Fig. 2E), was able to polymerize when HNE
was added. No polymers were found in the presence of OA
(Fig. 2G) or H89 (Fig. 2H). This experiment shows, for the
¢rst time, a condition in which phosphorylated tau has an
increased polymerization capacity, compared to that of un-
modi¢ed tau. When a HNE concentration-dependent experi-
ment was performed, it was found that the maximum propor-
tion of assembled tau could be obtained at 2 mM HNE (Fig.
3), but only for fully phosphorylated tau. In fact, unphos-
phorylated or partially (in the absence of GSK3 or PKA
modi¢cation) phosphorylated tau, is unable to fully assemble
under the same conditions (Fig. 3) although a very small
amount of tau aggregates could be observed in the absence
of PKA modi¢cation. These results indicate that phosphory-
lation of tau by GSK3 or PKA is required for tau assembly in
the presence of HNE. Assembled polymers appear in bundled
form, probably due to the crosslinking characteristics of HNE
[25], a feature that has been also reported in other peroxidant
conditions [26,27]. The assembled polymers have an estimated
diameter of 2^3 nm, although at high HNE concentrations,
straight ¢laments with a diameter of 10^12 nm were also
found (Fig. 3).
3.3. A short tau peptide could be assembled in the presence of
HNE and the absence of phosphorylation
In previous works it has been described that a peptide
present in the third tubulin-binding repeat of tau protein
was able to self-assemble in the presence of sulfate glycosami-
noglycans [10]. This peptide is not phosphorylated in normal
or pathological conditions.
To test if it could polymerize in the presence of HNE, an
experiment similar to that of Fig. 2F was carried out. Our
result indicates that 1 mM HNE facilitates the polymerization
of this tau peptide, forming 2^3 nm assembled polymers (data
not shown).
4. Discussion
For the ¢rst time, this work describes conditions in which
Fig. 2. Assembly of phosphorylated tau into ¢laments in the pres-
ence of HNE. E¡ect of LiCl in the reaction of tau with ab 12E8
(A) and PHF-1 (B) and that of H89 in the reaction of tau with ab
PHF-1 (C) or ab 128E (D). Puri¢ed phosphorylated tau was incu-
bated in the presence of di¡erent HNE concentrations and the pres-
ence of polymers was determined by electron microscopy. The ¢gure
shows the samples for recombinant tau+HNE (E), phosphorylated
tau+HNE (F), phosphorylated tau (in presence of LiCl)+HNE (G)
and phosphorylated tau3HNE (H).
Fig. 3. E¡ect of HNE concentration on tau assembly. A: Increasing
concentrations of HNE were added to unphosphorylated (F), parti-
ally phosphorylated (GSK3 modi¢cation lithium inhibited) (8),
H89 inhibited (b), or phosphorylated (R) tau protein, and the
amount of polymers assembled at di¡erent concentrations was mea-
sured by electron microscopy and sedimentation [10]. The morphol-
ogy obtained for phosphotau polymers in the presence of 1 mM
HNE is shown in B. The presence of two types of polymers 2^3 nm
or 10^12 nm wide is shown. Bar indicates 200 nM.
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phosphorylated tau shows a higher capacity to assemble than
unphosphorylated tau. It involves the combined e¡ects of tau
phosphorylation and reaction of tau with a product of lipid
peroxidation generated by oxidative damaged HNE. In a pre-
vious report it was indicated that a primary result of both
e¡ects was a conformational change of tau protein [14].
Now, it is indicated that such conformational change may
be critical to the formation of ¢brillar polymers. The phos-
phorylation of tau protein required for the assembly takes
place in at least three of the sites modi¢ed in AD [28]; sites
that are modi¢ed by GSK3 [22] and by a non-proline directed
protein kinase, probably PKA [29] or MAPRK [30]. GSK3
and PKA phosphorylation is needed for tau assembly in the
presence of HNE.
GSK3 activity is regulated by proteins such as amyloid L or
presenilins [31,32] that are directly involved in the onset of the
familiar type of AD [33], and, in this way, those proteins
could facilitate tau phosphorylation at some proline directed
phosphorylation sites, like those recognized by ab Tau-1 (in
negative form) or that of ab PHF-1 (in positive form). Lipid
peroxidation results from reactive oxygen species reactions
with polyunsaturated fatty acids forming secondary reactive
aldehydes like HNE [25]. Thus, it can be postulated that in
both features, aberrant tau phosphorylation takes place dur-
ing times of oxidative stress, the formation of tau polymers
could also take place.
Consistent with this potential coordination of these events
several kinases are known to be increased by oxidative stress,
e.g. MAPRK and p38 [34]. The previous points could be dis-
cussed by proposing a working model to take into account the
role of oxidative damage in inducing the pathological sequels
of AD [35] (Fig. 4).
Oxidative stress could occur in aged neurons by the pres-
ence of molecules like AL that could play a direct role in the
induction of oxidative stress [36]. On the other hand, the for-
mation of AL could be favored by the presence of mutated
PS1 [37]. The oxidative stress could result in oxidative damage
to lipids, the presence of lipid peroxidation, and the formation
of hydroxynonenal (HNE) and other reactive aldehydes
[16,38] and is found as an adduct to proteins of NFts [14,16].
HNE is a highly toxic agent, whose toxicity can be partially
blocked by cysteine containing proteins like ApoE2 or ApoE3
but not by ApoE4 [39]. If not blocked HNE can easily pass
among neuronal compartments and bind to tau protein [17].
If tau is phosphorylated, the reaction with HNE modi¢es its
conformation [14] and, as shown here, promotes its assembly
into ¢brillar polymers resembling NFTs [40]. These ¢bers are
similar, in form, to the narrow tau ¢laments of 2^3 nm found
in NFTs [41]. Additionally, wider polymers similar in form to
straight ¢laments of NFTs were found. Phosphorylation
could facilitate a tau conformational change that may allow
the interaction of HNE with those tau regions mainly in-
volved in polymer formation. One of these regions is the third
tubulin-binding motif present in tau molecule. However, a
major concern is that the in vitro concentrations of HNE
needed to clearly induce tau polymerization are in the milli-
molar range (although some polymers could be found at a
lower concentration), and it is not known if, in vivo, HNE
concentration could go that high.
Independently, the formation of tau polymers could also
probably occur in pathological conditions if sGAG are
present in the cytosol due to leakage of membrane compart-
ments (where sGAG and proteoglycans should be located)
[42]. In this way, membrane damage could be very important
to the formation of tau polymers, assembled by the interac-
tion of the protein with sGAG [10,11] or with HNE (this
work), although, in the second case, tau polymerization could
be accelerated by the phosphorylation of the protein. Addi-
tionally, the existence of other compounds apart from sGAG
or HNE that could facilitate tau assembly in di¡erent tau
pathologies (taupathies) could not be excluded.
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